75%Confidence
0Views
FDASource
2026-03-27Date
Summary
Harvard Drug Group's recall of Midodrine tablets due to defective blister packaging highlights packaging quality issues that could affect patient safety and medication efficacy for this hypotension treatment. This may trigger increased FDA scrutiny of Major Pharmaceuticals' packaging operations and could temporarily disrupt supply of this generic medication.
Actionable: Healthcare providers should check their Midodrine inventory for affected lots and verify packaging integrity before dispensing.
AI Confidence: 75%
Data Points
firmThe Harvard Drug Group LLC
classificationClass II
statusOngoing
distributionNationwide US.
productMidodrine Hydrochloride Tablets, USP, 5 mg, 50 Tablets (5 x 10 blister packs), Rx only, Packaged and Distributed by: Major Pharmaceuticals, Indianapol
Get Signals Instantly
Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.
Subscribe Now